Stallergenes Greer Ltd
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Stallergenes Greer Ltd
Stallergenes Greer's Delisting To Focus Leadership On Facility Issues
The acquisition of the UK-headquartered leading allergy immunotherapy firm by its private majority shareholder is expected to remove the distraction of stock market listing obligations for management.
Stallergenes' Mite Allergy Results An Early Leaving Present For Retiring CEO
Positive Phase III data with its sublingual house dust allergy tablet heralds a likely increase in competition in the US allergy sector in the years to come and also provide an early leaving present for the company's retiring CEO.
Pipeline Watch: Phase III Starts With Atezolizumab, CNTX-4975 And WTX101
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Can Denmark's ALK-Abello Crack The US Allergy Market?
Increasing patient and doctor awareness of sublingual anti-allergy tablets in the US, while at the same time cutting and rationalizing its product portfolio, are components of a new three-year business strategy aimed at making Denmark's ALK-Abello a less-niche player in the global allergy market.
- Other Names / Subsidiaries
- Alegro Pharma S.R.L.
- Greer Laboratories, Inc.
- Medic Savoure Limited
- Stallergenes Greer plc
- Stallergenes S.A.
- Stallergenes SAS
- Stallergenes S.A.S.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.